Machine learning based prediction and the influence of complement - Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial.


Journal

Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478

Informations de publication

Date de publication:
07 2022
Historique:
received: 10 11 2021
revised: 21 02 2022
accepted: 21 03 2022
pubmed: 29 3 2022
medline: 1 6 2022
entrez: 28 3 2022
Statut: ppublish

Résumé

Functional outcomes are important measures in the overall clinical course of psychosis and individuals at clinical high-risk (CHR), however, prediction of functional outcome remains difficult based on clinical information alone. In the first part of this study, we evaluated whether a combination of biological and clinical variables could predict future functional outcome in CHR individuals. The complement and coagulation pathways have previously been identified as being of relevance to the pathophysiology of psychosis and have been found to contribute to the prediction of clinical outcome in CHR participants. Hence, in the second part we extended the analysis to evaluate specifically the relationship of complement and coagulation proteins with psychotic symptoms and functional outcome in CHR. We carried out plasma proteomics and measured plasma cytokine levels, and erythrocyte membrane fatty acid levels in a sub-sample (n = 158) from the NEURAPRO clinical trial at baseline and 6 months follow up. Functional outcome was measured using Social and Occupational Functional assessment Score (SOFAS) scale. Firstly, we used support vector machine learning techniques to develop predictive models for functional outcome at 12 months. Secondly, we developed linear regression models to understand the association between 6-month follow-up levels of complement and coagulation proteins with 6-month follow-up measures of positive symptoms summary (PSS) scores and functional outcome. A prediction model based on clinical and biological data including the plasma proteome, erythrocyte fatty acids and cytokines, poorly predicted functional outcome at 12 months follow-up in CHR participants. In linear regression models, four complement and coagulation proteins (coagulation protein X, Complement C1r subcomponent like protein, Complement C4A & Complement C5) indicated a significant association with functional outcome; and two proteins (coagulation factor IX and complement C5) positively associated with the PSS score. Our study does not provide support for the utility of cytokines, proteomic or fatty acid data for prediction of functional outcomes in individuals at high-risk for psychosis. However, the association of complement protein levels with clinical outcome suggests a role for the complement system and the activity of its related pathway in the functional impairment and positive symptom severity of CHR patients.

Sections du résumé

BACKGROUND
Functional outcomes are important measures in the overall clinical course of psychosis and individuals at clinical high-risk (CHR), however, prediction of functional outcome remains difficult based on clinical information alone. In the first part of this study, we evaluated whether a combination of biological and clinical variables could predict future functional outcome in CHR individuals. The complement and coagulation pathways have previously been identified as being of relevance to the pathophysiology of psychosis and have been found to contribute to the prediction of clinical outcome in CHR participants. Hence, in the second part we extended the analysis to evaluate specifically the relationship of complement and coagulation proteins with psychotic symptoms and functional outcome in CHR.
MATERIALS AND METHODS
We carried out plasma proteomics and measured plasma cytokine levels, and erythrocyte membrane fatty acid levels in a sub-sample (n = 158) from the NEURAPRO clinical trial at baseline and 6 months follow up. Functional outcome was measured using Social and Occupational Functional assessment Score (SOFAS) scale. Firstly, we used support vector machine learning techniques to develop predictive models for functional outcome at 12 months. Secondly, we developed linear regression models to understand the association between 6-month follow-up levels of complement and coagulation proteins with 6-month follow-up measures of positive symptoms summary (PSS) scores and functional outcome.
RESULTS AND CONCLUSION
A prediction model based on clinical and biological data including the plasma proteome, erythrocyte fatty acids and cytokines, poorly predicted functional outcome at 12 months follow-up in CHR participants. In linear regression models, four complement and coagulation proteins (coagulation protein X, Complement C1r subcomponent like protein, Complement C4A & Complement C5) indicated a significant association with functional outcome; and two proteins (coagulation factor IX and complement C5) positively associated with the PSS score. Our study does not provide support for the utility of cytokines, proteomic or fatty acid data for prediction of functional outcomes in individuals at high-risk for psychosis. However, the association of complement protein levels with clinical outcome suggests a role for the complement system and the activity of its related pathway in the functional impairment and positive symptom severity of CHR patients.

Identifiants

pubmed: 35341915
pii: S0889-1591(22)00081-2
doi: 10.1016/j.bbi.2022.03.013
pii:
doi:

Substances chimiques

Complement C5 0
Cytokines 0
Fatty Acids 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

50-60

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Subash Raj Susai (SR)

Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Electronic address: subashrajsusai@rcsi.ie.

David Mongan (D)

Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Colm Healy (C)

Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Mary Cannon (M)

Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Gerard Cagney (G)

School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland.

Kieran Wynne (K)

School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland; Systems Biology Ireland, University College Dublin, Dublin, Ireland.

Jonah F Byrne (JF)

Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Connie Markulev (C)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Orygen, 35 Poplar Rd, Parkville 3052, Australia.

Miriam R Schäfer (MR)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Orygen, 35 Poplar Rd, Parkville 3052, Australia.

Maximus Berger (M)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Department of Psychiatry and Psychotherapy, University of Bern, Switzerland.

Nilufar Mossaheb (N)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Monika Schlögelhofer (M)

BioPsyC-Biopsychosocial Corporation - Non-Profit Association for Research Funding, Vienna, Austria.

Stefan Smesny (S)

Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.

Ian B Hickie (IB)

Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.

Gregor E Berger (GE)

Child and Adolescent Psychiatric Service of the Canton of Zurich, Zürich, Switzerland.

Eric Y H Chen (EYH)

Department of Psychiatry, University of Hong Kong, Pok Fu Lam, Hong Kong.

Lieuwe de Haan (L)

Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands.

Dorien H Nieman (DH)

Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands.

Merete Nordentoft (M)

Mental Health Center Copenhagen, Department of Clinical Medicine, Copenhagen University Hospital, Denmark.

Anita Riecher-Rössler (A)

Medical Faculty, University of Basel, Switzerland.

Swapna Verma (S)

Institute of Mental Health, Singapore, Singapore.

Rebekah Street (R)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Orygen, 35 Poplar Rd, Parkville 3052, Australia.

Andrew Thompson (A)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Orygen, 35 Poplar Rd, Parkville 3052, Australia.

Alison Ruth Yung (A)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, Geelong, Australia; School of Health Sciences, University of Manchester, UK.

Barnaby Nelson (B)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Orygen, 35 Poplar Rd, Parkville 3052, Australia.

Patrick D McGorry (PD)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Orygen, 35 Poplar Rd, Parkville 3052, Australia.

Melanie Föcking (M)

Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

G Paul Amminger (G)

Centre for Youth Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; Orygen, 35 Poplar Rd, Parkville 3052, Australia.

David Cotter (D)

Department of Psychiatry, RCSI University of Medicine and Health Sciences, Dublin, Ireland. Electronic address: drcotter@rcsi.ie.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH